Indications

PROLIA® IS A MEDICINE FOR THE TREATMENT OF OSTEOPOROSIS

Prolia® is therapeutically indicated for:1
  • Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women, Prolia® significantly reduces the risk of vertebral, non-vertebral and hip fractures.
  • Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, Prolia® significantly reduces the risk of vertebral fractures.
  • Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.
The recommended dose of Prolia® is 60 mg administered as a single subcutaneous injection once every 6 months into the thigh, abdomen or upper arm. Patients must be adequately supplemented with calcium and vitamin D.1
Click here to read the full Prolia® Summary of Product of Characteristics.

References:
  1. Prolia® (denosumab) Summary of Product Characteristics. Amgen.

SMPC

The information contained in this site is for healthcare professionals only

I am a patient
I am a member of the public